Thr2055

Site Information
MAFsILNtPkkLGNs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 472502
Associated spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 35 , 36 , 37 , 38 , 39 ) , mass spectrometry (in vitro) ( 8 , 14 , 34 ) , phospho-antibody ( 8 ) , western blotting ( 8 )
Disease tissue studied:	breast cancer ( 7 , 13 ) , breast ductal carcinoma ( 7 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, surrounding tissue ( 3 ) , breast cancer, triple negative ( 3 , 7 ) , cervical cancer ( 29 ) , cervical adenocarcinoma ( 29 ) , leukemia ( 15 , 36 , 37 ) , acute myelogenous leukemia ( 15 ) , chronic myelogenous leukemia ( 36 , 37 ) , lung cancer ( 5 , 13 , 27 ) , non-small cell lung cancer ( 13 , 27 ) , non-small cell lung adenocarcinoma ( 5 ) , ovarian cancer ( 7 ) , melanoma skin cancer ( 4 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 9 ) , breast ( 3 , 7 ) , BT-20 (breast cell) ( 13 ) , BT-549 (breast cell) ( 13 ) , Calu 6 (pulmonary) ( 13 ) , H2009 (pulmonary) ( 13 ) , H2077 (pulmonary) ( 13 ) , H2887 (pulmonary) ( 13 ) , H322M (pulmonary) ( 13 ) , HCC2279 (pulmonary) ( 13 ) , HCC366 (pulmonary) ( 13 ) , HCC78 (pulmonary) ( 13 ) , HeLa (cervical) ( 2 , 6 , 8 , 12 , 16 , 17 , 22 , 33 , 35 ) , HeLa S3 (cervical) ( 21 , 29 ) , HOP62 (pulmonary) ( 13 ) , HUES-7 ('stem, embryonic') ( 30 ) , Jurkat (T lymphocyte) ( 10 , 18 , 19 , 20 , 23 , 24 , 25 , 26 , 28 , 31 , 32 ) , K562 (erythroid) ( 36 , 37 , 38 , 39 ) , KG-1 (myeloid) ( 15 ) , lung ( 27 ) , MDA-MB-231 (breast cell) ( 13 ) , MDA-MB-468 (breast cell) ( 13 ) , NCI-H1395 (pulmonary) ( 13 ) , NCI-H1568 (pulmonary) ( 13 ) , NCI-H1648 (pulmonary) ( 13 ) , NCI-H2030 (pulmonary) ( 13 ) , NCI-H2172 (pulmonary) ( 13 ) , NCI-H322 (pulmonary) ( 13 ) , NCI-H520 (squamous) ( 13 ) , NCI-H647 (pulmonary) ( 13 ) , ovary ( 7 ) , PC9 (pulmonary) ( 5 , 13 ) , PC9-IR (pulmonary) ( 5 ) , WM239A (melanocyte) ( 4 )

Upstream Regulation
Regulatory protein:	TBK1 (human) ( 9 )
Putative in vivo kinases:	CDK1 (human) ( 8 )
Kinases, in vitro:	AurB (human) ( 14 ) , CDK1 (human) ( 8 , 34 )
Putative upstream phosphatases:	PPP2CA (human) ( 8 )
Treatments:	MLN8054 ( 22 ) , Y27632 ( 16 )

Downstream Regulation
Effects of modification on biological processes:	cytoskeletal reorganization ( 8 )

References
1	Keshri R, Rajeevan A, Kotak S (2020) PP2A--B55¿¿ counteracts Cdk1 and regulates proper spindle orientation through the cortical dynein adaptor NuMA. J Cell Sci 32591484 Curated Info
2	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
3	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
4	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
5	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
6	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
7	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
8	Kotak S, Busso C, Gönczy P (2013) NuMA phosphorylation by CDK1 couples mitotic progression with cortical dynein function. EMBO J 32, 2517-29 23921553 Curated Info
9	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
10	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
11	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
12	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
13	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
14	Hengeveld RC, et al. (2012) Development of a chemical genetic approach for human aurora B kinase identifies novel substrates of the chromosomal passenger complex. Mol Cell Proteomics 11, 47-59 22267324 Curated Info
15	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
16	Nishioka T, Nakayama M, Amano M, Kaibuchi K (2012) Proteomic screening for Rho-kinase substrates by combining kinase and phosphatase inhibitors with 14-3-3ζ affinity chromatography. Cell Struct Funct 37, 39-48 22251793 Curated Info
17	Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540 21857030 Curated Info
18	Guo A (2011) CST Curation Set: 12436; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
19	Guo A (2011) CST Curation Set: 12437; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
20	Zhou J (2011) CST Curation Set: 12319; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Curated Info
21	Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457 20860994 Curated Info
22	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
23	Possemato A (2010) CST Curation Set: 10274; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (G/N/L)p[ST] Curated Info
24	Possemato A (2010) CST Curation Set: 9958; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST] Curated Info
25	Possemato A (2010) CST Curation Set: 9959; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST] Curated Info
26	Possemato A (2010) CST Curation Set: 9696; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST] Curated Info
27	Rikova K (2010) CST Curation Set: 9457; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
28	Possemato A (2010) CST Curation Set: 9438; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
29	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
30	Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26 19664995 Curated Info
31	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
32	Possemato A (2008) CST Curation Set: 5276; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
33	McNulty DE, Annan RS (2008) Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics 7, 971-80 18212344 Curated Info
34	Blethrow JD, Glavy JS, Morgan DO, Shokat KM (2008) Covalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates. Proc Natl Acad Sci U S A 105, 1442-7 18234856 Curated Info
35	Beausoleil SA, et al. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24, 1285-92 16964243 Curated Info
36	Moritz A (2005) CST Curation Set: 595; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
37	Moritz A (2005) CST Curation Set: 596; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
38	Moritz A (2005) CST Curation Set: 597; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
39	Moritz A (2005) CST Curation Set: 598; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info